眼眶曲霉病：伏立康唑——新的标准治疗方法？
Orbital aspergillosis: voriconazole - the new standard treatment?
作者信息
Ohlstein Derek H, Hooten Claudia, Perez Javier, Clark Charles L, Samy Hazem
机构信息
Neuro-Ophthalmology Service, Department of Ophthalmology, University of Florida, Gainesville, Fla., USA.
出版信息
Case Rep Ophthalmol. 2012 Jan;3(1):46-53. doi: 10.1159/000336276. Epub 2012 Feb 4.
BACKGROUND/AIM: To describe a case of invasive orbital aspergillosis and evaluate treatments and outcomes.
METHODS
A case report and review of orbital aspergillosis treatment with voriconazole in the English language literature.
CONCLUSION
Amphotericin B with debridement is the current standard of care for orbital aspergillosis; however, its prognosis is unfavorable. When compared to amphotericin B, voriconazole demonstrates a survival benefit, has less systemic toxicity, and is better tolerated by patients. While a prospective trial comparing amphotericin B to voriconazole in orbital aspergillosis is not feasible, there is evidence to support the use of voriconazole as primary therapy.
背景/目的：描述一例侵袭性眼眶曲霉病病例，并评估其治疗方法及结果。
方法
一份病例报告，并对英文文献中伏立康唑治疗眼眶曲霉病的情况进行综述。
结论
两性霉素B联合清创术是目前眼眶曲霉病的标准治疗方法；然而，其预后不佳。与两性霉素B相比，伏立康唑具有生存优势，全身毒性较小，患者耐受性更好。虽然在眼眶曲霉病中比较两性霉素B和伏立康唑的前瞻性试验不可行，但有证据支持将伏立康唑作为一线治疗药物。
Zotero 插件